Biosimilar developer Celltrion has resubmitted its Biologics License Application (BLA) for a proposed rituximab biosimilar, CT-P10, to the FDA for regulatory consideration. The company received a Complete Response Letter for the drug in April 2018, after having received an earlier warning letter from the agency that raised concerns about the company’s manufacturing processes.
Biosimilar developer Celltrion has resubmitted its Biologics License Application (BLA) for a proposed rituximab biosimilar, CT-P10, to the FDA for regulatory consideration. The company received a Complete Response Letter (CRL) for the drug in April 2018, after having received an earlier warning letter from the agency that raised concerns about the company’s manufacturing processes.
The warning letter detailed “poor aseptic behavior,” including an observation made during an inspection that an operator created the risk of microbial contamination during the aseptic filling of vials, and that, even after revising its aseptic technique procedures for setup and filling, Celltrion’s procedure allowed for contamination of product-contact surfaces followed by disinfection rather than preventing sterile equipment from becoming contaminated.
Other issues noted in the warning letter included smoke study deficiencies, media fill deficiencies, problems with vial stoppers, the presence of visible particles in finished drug product, and deficient environmental monitoring.
“Celltrion has made progress addressing the concerns raised by the FDA in the warning letter and is committed to working with the Agency to fully resolve all outstanding issues with the highest priority and urgency,” said the company in a statement. It also noted that the FDA has notified the company of its reinspection schedule for the facility in question, and it has confirmed that it will resume the review procedure for biosimilars upon BLA resubmission.
Celltiron will also resubmit a BLA for its proposed trastuzumab biosimilar, CT-P6, to the FDA in June; the company received a CRL for the trastuzumab product on the same day as the CRL for the rituximab biosimilar. In a notice to shareholders, Celltrion explained that it hopes to obtain US approval for the 2 biosimilars before the end of 2018.
In the European Union, Celltrion’s rituximab and trastuzumab biosimilars are both authorized for marketing and are sold under the brand names Truxima and Herzuma, respectively.
What Stands in the Way of Biosimilar Use Across MENA Countries?
May 21st 2025Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the Middle East and North Africa (MENA) region is tangled in a web of distrust, inconsistent policies, and deep-rooted cultural preferences for branded drugs.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.